PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl

Blood

Volumn 88, Issue 5, 1996, Pages 1542-1550

  Jain, Suresh K ^b   Šuša, Mira ^b   Keeler, Marilyn L ^b   Carlesso, Nadia ^b   Druker, Brian ^b   Varticovski, Lyuba ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; PROTEIN SUBUNIT; TRIPHOSPHOINOSITIDE;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HEMATOPOIETIC CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSGENIC MOUSE;

EID: 0029815798     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.5.1542.bloodjournal8851542     Document Type: Article

References (49)

1. Groffen J, Stephonson JR, Heisterkamp N, deKlein A, Bartam CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within limited region, bcr, on chromosome 22. Cell 36:93, 1984
2. Clark SS, Srist WM, Witte ON: Molecular pathogenesis of pH-positive leukemias. Annu Rev Med 40:113, 1989
3. Daley GQ, McLaughlin J, Witte ON, Baltimore D: The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 237:532, 1987
4. McLaughlin J, Chianese E, Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84:6558, 1987
5. Hariharan IK, Adams JM, Cory S: BCR-abl oncogene renders myeloid cell line factor independent. Oncogene 3:387, 1988
6. Daley GQ, Baltimore D: Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc Natl Acad Sci USA 85:9312, 1988
7. Kelliher MA, McLaughghlin J, Witte ON, Rosenberg N : Induction of chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 87:6649, 1990
8. Lugo TG, Witte ON: The bcr/abl oncogene transforms rat-1 cells and cooperates with c-myc. Mol Cell Biol 9:1263, 1989
9. Daley GQ, Van Etten RA, Jackson PK, Bernards A, Baltimore D: Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol Cell Biol 12:1864, 1992
10. McWhirter JR, Wang JYJ: An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12:1533, 1993
11. Wetzler M, Tapaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R: Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 92:1925, 1993
12. Resh MD, Ling H-P: Identification of a 32K plasma membrane protein that binds to the myristoylated amino-terminal sequence of p60v-src. Nature 346:84, 1990
13. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley L: Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 11:1107, 1991
14. src prevents both myristoylation and morphological transformation. Proc Natl Acad Sci USA 82:4625, 1985
15. Skorski T, Kanakaraj P, Skoska MN, Ratajczak MZ, Wen S-C, Zon G, Gewitz AM, Perussia B, Calabretta B: Phosphatidylinositol 3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726, 1995
16. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S: Oncogenes and signal transduction. Cell 64:281, 1991
17. Heldin C-H: Dimerization of cell surface receptors in signal transduction. Cell 80:213, 1995
18. Varticovski L, Harrison-Findik D, Keeler ML, Susa M: Role of PI 3-kinase in mitogenesis. Biochim Biophys Acta 1226:1, 1994
19. Escobedo JA, Kaplan DR, Kavanaugh M, Turck C, Williams LT: A Phosphatidylinositol-3 kinase binds to platelet-derived growth factor receptor through a specific receptor sequence containing phosphotyrosine. Mol Cell Biol 11:1125, 1991
20. Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, Cantley LC: Phosphatidylinositol 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the p85 kD subunit. J Biol Chem 268:9478, 1993
21. Rordorf-Nikolic T, Van Horn DJ, Chen D, White MF, Backer JM: Regulation of phosphatidylinositol 3′-kinase by tyrosil phosphoproteins. J Biol Chem 270:3662, 1995
22. BCR/abl tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9:149, 1994
23. Macpherson I, in Kruse PF, Patterson MK (eds): Tissue Culture Methods and Applications. 1973, p 276
24. Kanazawa T, Keeler M, Varticovski L: Serine-rich region of the IL-2 receptor β chain is required for activation of phosphatidyl-inositol 3-kinase. Cell Immunol 156:1, 1994
25. Whitman M, Kaplan DR, Schaffhausen B, Cantley L: Association of phosphatidylinositol kinase activity with polyoma middle-T component for transformation. Nature 315:239, 1985
26. Varticovski L, Druker B, Morrison D, Cantley LC, Roberts T: The CSF-1 receptor associates with and activates PI 3-kinase. Nature 342:699, 1989
27. Susa M, Keeler ML, Varticovski L: Platelet-derived growth factor activates membrane-associated phosphatidyinositol 3-kinase and mediates its translocation from the cytosol. J Biol Chem 267:22951, 1992
28. Yoakim M, Hou W, Liu Y, Carpenter CL, Kapeller R, Schaffhausen BS: Interactions of polyoma virus middle T with SH2 domains of p85 subunit of PI 3-kinase. J Virol 66:54485, 1992
29. Harrison-Findik D, Susa M, Varticovski L: Association of phosphatidylinositol 3-kinase with She in chronic myelogenous leukemia cells. Oncogene 10:1385, 1995
30. Klippel A, Escobedo JA, Fantl W, Williams LT: The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor β receptor. Mol Cell Biol 12:1451, 1992
31. Fantl WJ, Escobedo JA. Martin GA, Turck CW, Del Rosario M, McCormick F, Williams LT: Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 69:413, 1992
32. Panayotou G, Bax B, Gout I, Federwisch M, Wroblowski B, Dhand R, Fry MJ, Blundell TL, Wollmer A, Waterfield MD: Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: Structural features and analysis of conformational changes. EMBO J 11:4261, 1992
33. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Rafnofski S, Lechleider RJ, Neel BG, Birge RB, Fajardo EJ, Chou MM, Hanafusa H, Schaffhausen B, Cantley L: SH2 domains recognize specific phosphopeptide sequences. Cell 72:767, 1993
34. Ponzetto C, Bardelli A, Maina F, Longati P, Panayotou G, Dhand R, Waterfield MD, Comoglio PM: A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. EMBO J 13:4600, 1993
35. Carpenter CL, Auger KR, Duckworth BC, Hou W-M, Schaffhausen B, Cantley LC: A tightly associated serine/threonine protein kinase regulates phosphoinositol 3-kinase activity. Mol Cell Biol 13:1657, 1993
36. Shoelson SE, Sivaraja M, Williams KP, Hu P, Schlessinger J, Weiss MA: Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation. EMBO J 12:795, 1993
37. Engelman A, Rosenberg N: Isolation of temperature-sensitive Abelson virus mutants by site-directed mutagenesis. Proc Natl Acad Sci USA 84:8021, 1987
38. Engelman A, Rosenberg N: Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J Virol 64:4242, 1990
39. Kabarowski JHS, Allen PB, Wiedemann LM: A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 13:5887, 1994
40. Kapeller R, Chen KS, Yoakim M, Schaffhausen BS, Backer J, White MF, Cantley LC, Ruderman NB: Mutations in the Juxtamembrane region of the insulin receptor impair activation of phosphatidylinositol 3-kinase by insulin. Mol Endocrinol 5:769, 1991
41. Ling LE, Drucker BJ, Cantley LC, Roberts TM: Transformation-defective mutants of polyoma middle T antigen associate with phosphatidylinositol 3-kinase (PI 3-kinase) but are unable to maintain wild-type levels of PI 3-kinase products in intact cells. J Virol 66:1702, 1992
42. Kelly KL, Ruderman NB, Chen KS: Phosphatidylinositol 3-kinase in isolated rat adipocytes. J Biol Chem 267:3423, 1992
43. Pendergast A-M, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175, 1993
44. BCR/ABL. J Biol Chem 269:5016, 1994
45. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ: Crk1 is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia, J Biol Chem 269:22925, 1994
46. Andoniou CE, Thien CBF, Langdon WY: Tumour induction by activated abl involves tyrosine phosphorylat ion of the product of the cbl oncogene. EMBO J 13:4515, 1994
47. Wang J, Auger KR, Jarvis L, Shi Y, Roberts TM: Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 270:12774, 1995
48. Meisner H, Conway BR, Hartley D, Czech MP: Interactions of Cbl with GRB2 and PI 3-kinase in activated Jurkat cells. Mol Cell Biol 15:3571, 1995
49. Fukazawa T, Reedquist KA, Trub T, Soltoff S, Panchamoorthy G, Druker B, Cantley L, Shoelson SE, Band H: The SH3 domain-binding T cell tyrosyl phosphoprotein p 120. J Biol Chem 270:19141, 1995